12 results
In situ, broadband measurement of the radio frequency attenuation length at Summit Station, Greenland
- J. A. Aguilar, P. Allison, J. J. Beatty, D. Besson, A. Bishop, O. Botner, S. Bouma, S. Buitink, M. Cataldo, B. A. Clark, Z. Curtis-Ginsberg, A. Connolly, P. Dasgupta, S. de Kockere, K. D. de Vries, C. Deaconu, M. A. DuVernois, C. Glaser, A. Hallgren, S. Hallmann, J. C. Hanson, B. Hendricks, C. Hornhuber, K. Hughes, A. Karle, J. L. Kelley, I. Kravchenko, R. Krebs, R. Lahmann, U. Latif, J. Mammo, Z. S. Meyers, K. Michaels, K. Mulrey, A. Nelles, A. Novikov, A. Nozdrina, E. Oberla, B. Oeyen, Y. Pan, H. Pandya, I. Plaisier, N. Punsuebsay, L. Pyras, D. Ryckbosch, O. Scholten, D. Seckel, M. F. H. Seikh, D. Smith, D. Southall, J. Torres, S. Toscano, D. Tosi, D. J. Van Den Broeck, N. van Eijndhoven, A. G. Vieregg, C. Welling, D. R. Williams, S. Wissel, R. Young, A. Zink
-
- Journal:
- Journal of Glaciology / Volume 68 / Issue 272 / December 2022
- Published online by Cambridge University Press:
- 30 May 2022, pp. 1234-1242
-
- Article
-
- You have access Access
- Open access
- HTML
- Export citation
-
Over the last 25 years, radiowave detection of neutrino-generated signals, using cold polar ice as the neutrino target, has emerged as perhaps the most promising technique for detection of extragalactic ultra-high energy neutrinos (corresponding to neutrino energies in excess of 0.01 Joules, or 1017 electron volts). During the summer of 2021 and in tandem with the initial deployment of the Radio Neutrino Observatory in Greenland (RNO-G), we conducted radioglaciological measurements at Summit Station, Greenland to refine our understanding of the ice target. We report the result of one such measurement, the radio-frequency electric field attenuation length $L_\alpha$
. We find an approximately linear dependence of $L_\alpha$
on frequency with the best fit of the average field attenuation for the upper 1500 m of ice: $\langle L_\alpha \rangle = ( ( 1154 \pm 121) - ( 0.81 \pm 0.14) \, ( \nu /{\rm MHz}) ) \,{\rm m}$
for frequencies ν ∈ [145 − 350] MHz.
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
- J.J.S. Kooij, D. Bijlenga, L. Salerno, R. Jaeschke, I. Bitter, J. Balázs, J. Thome, G. Dom, S. Kasper, C. Nunes Filipe, S. Stes, P. Mohr, S. Leppämäki, M. Casas, J. Bobes, J.M. Mccarthy, V. Richarte, A. Kjems Philipsen, A. Pehlivanidis, A. Niemela, B. Styr, B. Semerci, B. Bolea-Alamanac, D. Edvinsson, D. Baeyens, D. Wynchank, E. Sobanski, A. Philipsen, F. McNicholas, H. Caci, I. Mihailescu, I. Manor, I. Dobrescu, T. Saito, J. Krause, J. Fayyad, J.A. Ramos-Quiroga, K. Foeken, F. Rad, M. Adamou, M. Ohlmeier, M. Fitzgerald, M. Gill, M. Lensing, N. Motavalli Mukaddes, P. Brudkiewicz, P. Gustafsson, P. Tani, P. Oswald, P.J. Carpentier, P. De Rossi, R. Delorme, S. Markovska Simoska, S. Pallanti, S. Young, S. Bejerot, T. Lehtonen, J. Kustow, U. Müller-Sedgwick, T. Hirvikoski, V. Pironti, Y. Ginsberg, Z. Félegyházy, M.P. Garcia-Portilla, P. Asherson
-
- Journal:
- European Psychiatry / Volume 56 / Issue 1 / February 2019
- Published online by Cambridge University Press:
- 16 November 2018, pp. 14-34
-
- Article
-
- You have access Access
- Open access
- HTML
- Export citation
-
Background Attention-deficit/hyperactivity disorder (ADHD) is among the most common psychiatric disorders of childhood that often persists into adulthood and old age. Yet ADHD is currently underdiagnosed and undertreated in many European countries, leading to chronicity of symptoms and impairment, due to lack of, or ineffective treatment, and higher costs of illness.
Methods The European Network Adult ADHD and the Section for Neurodevelopmental Disorders Across the Lifespan (NDAL) of the European Psychiatric Association (EPA), aim to increase awareness and knowledge of adult ADHD in and outside Europe. This Updated European Consensus Statement aims to support clinicians with research evidence and clinical experience from 63 experts of European and other countries in which ADHD in adults is recognized and treated.
Results Besides reviewing the latest research on prevalence, persistence, genetics and neurobiology of ADHD, three major questions are addressed: (1) What is the clinical picture of ADHD in adults? (2) How should ADHD be properly diagnosed in adults? (3) How should adult ADHDbe effectively treated?
Conclusions ADHD often presents as a lifelong impairing condition. The stigma surrounding ADHD, mainly due to lack of knowledge, increases the suffering of patients. Education on the lifespan perspective, diagnostic assessment, and treatment of ADHD must increase for students of general and mental health, and for psychiatry professionals. Instruments for screening and diagnosis of ADHD in adults are available, as are effective evidence-based treatments for ADHD and its negative outcomes. More research is needed on gender differences, and in older adults with ADHD.
Reassessing Carbamazepine in the Treatment of Bipolar Disorder Clinical Implications of New Data
- Terence A. Ketter, David L. Ginsberg, Hagop S. Akiskal, Paul E. Keck, Jr, Richard H. Weisler, Robert M.A. Hirschfeld, Eric Hollander
-
- Journal:
- CNS Spectrums / Volume 10 / Issue 6 / June 2005
- Published online by Cambridge University Press:
- 08 April 2017, pp. 1-2
-
- Article
- Export citation
-
This monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions.
Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight.) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.
New Challenges for Anxiety Disorders: Where Treatment, Resilience, and Economic Priority Converge
- Mark H. Pollack, Murray B. Stein, Jonathan R.T. Davidson, David L. Ginsberg
-
- Journal:
- CNS Spectrums / Volume 9 / Issue 4 / April 2004
- Published online by Cambridge University Press:
- 07 November 2014, pp. 1-4
-
- Article
- Export citation
-
Anxiety disorders are highly prevalent, are increasing in incidence, affect individuals early in life, and significantly impact health care and quality of life. As such, they are serious public health problems that deserve attention now and in the future. Over the last 10–20 years, there has been marked improvement in pharmacologic and psychosocial interventions for anxiety. Due to their broad spectrum of efficacy against common comorbidities and lack of association with abuse and dependence, serotonergic and mixed serotonergic noradrenergic antidepressants are first-line therapies for anxiety disorders. Benzodiazepines are still widely used in clinical practice because they are well tolerated and work quickly and effectively. Other medications that are emerging as potentially useful for selected populations with anxiety include atypical neuroleptics and anticonvulsants. Cognitive-behavioral therapy (CBT) is at least as effective as medication for many patients with anxiety disorders and facilitates maintenance of benefit over the long term. Resilience, the capacity to bounce back from adversity, can be reliably measured with a psychometrically valid scale, the Connor-Davidson Resilience Scale. Compared with the general population, individuals with anxiety disorders exhibit decreased resilience. Studies have shown that pharmacologic treatment combined with CBT may increase resilience within 2–3 months. Emerging neurobiologic research indicates that noradrenergic pathways and 5-HT2 transporter efficiency may mediate effects on resiliency.
Remission-Oriented Treatment of Depression
- Robert H. Howland, Madhukar H. Trivedi, Philip T. Ninan, David L. Ginsberg
-
- Journal:
- CNS Spectrums / Volume 6 / Issue 1 / January 2001
- Published online by Cambridge University Press:
- 07 November 2014, pp. 1-12
-
- Article
- Export citation
-
Given the wide variety of available antidepressant therapies, an important question is how effective are we in treating depression? In clinical research trials of antidepressants, a treatment response is defined as a 50% or greater improvement in depressive symptoms, whereas remission is defined as having minimal or absent symptoms at the end of treatment. Approximately 50% of patients treated with antidepressants have a treatment response, but only about 25% have a complete remission. Many treatment responders therefore have residual symptoms despite adequate treatment. This is critically important because depressed patients with residual symptoms, even though mild in severity, still have significant functional impairment, have a high risk of relapsing into a more severe episode, and may have a more chronic course of illness. Such patients also do not show a full functional recovery from their depression. Recent comparative studies have found that remission rates are significantly higher with venlafaxine (Effexor) compared to serotonin reuptake inhibitors, which might be due to their different effects on neurotransmitter systems. The use of medication combinations, having additive and/or synergistic antidepressant effects, or adding psychotherapy following a course of pharmacotherapy also can be used to treat residual symptoms and lead to a more complete remission.
Contributors
-
- By Leonard A. Adler, Henrik Anckarsäter, L. Eugene Arnold, Philip J. Asherson, Russell Barkley, Joseph Biederman, Andrew D. Blackwell, Jessica Bramham, Thomas E. Brown, Richard Bruggeman, Jan K. Buitelaar, C. Keith Conners, Jonathan H. Dowson, Steve V. Faraone, Christopher Gibbins, Christopher Gillberg, I. Carina Gillberg, Ylva Ginsberg, Laurence L. Greenhill, Julia D. Hunter, Cornelis C. Kan, Ronald C. Kessler, Scott H. Kollins, J. J. Sandra Kooij, Johanna Krause, Jonna Kuntsi, Florence Levy, Stephen P. McDermott, Gráinne McLoughlin, Mitul A. Mehta, Asko Niemela, Eleni Paliokosta, Yannis Paloyelis, Vangelis Pappas, Patricia Quinn, Maria Råstam, Doris Ryffel, David Shaw, Seija Sirviö, Thomas Spencer, Lacramioara Spetie, Siegfried Tuinier, Fiona E. van Dijk, Anne M. D. N. van Lammeren, Wim J. C. Verbeeck, Margaret Weiss, Timothy E. Wilens, Kiriakos Xenitidis
- Edited by Jan K. Buitelaar, Cornelis C. Kan, Philip Asherson, Institute of Psychiatry, London
-
- Book:
- ADHD in Adults
- Published online:
- 04 April 2011
- Print publication:
- 03 March 2011, pp vii-ix
-
- Chapter
- Export citation
Contributors
-
- By R. J. Aitken, Gokhan Akkoyunlu, David F. Albertini, Christiani A. Amorim, R. A. Anderson, Baris Ata, Pedro N. Barri, Mohamed A. Bedaiwy, Rosita Bergström, Veronica Bianchi, Montserrat Boada, Paolo Boffetta, Andrea Borini, Karina Braga Ribeiro, Peter R. Brinsden, Ralph L. Brinster, Jason G. Bromer, A. L. Caplan, Chian Ri-Cheng, Ina N. Cholst, A. Ciobanu, Megan Clowse, Ana Cobo, Susannah C. Copland, John K. Critser, B. J. Curry, Giuseppe Del Priore, M. De Vos, Marie-Madeleine Dolmans, Javier Domingo, Jacques Donnez, David H. Edgar, Nanette R. Elster, Carol Fabian, Gregory M. Fahy, Tommaso Falcone, Debra Friedman, Jill P. Ginsberg, Debra A. Gook, Julie R. Gralow, Elizabeth Grill, Sebastien Gouy, Xu Han, Lisa M. Harlan-Williams, Outi Hovatta MD, Wayland Hsiao, Zhongwei Huang, E. Isachenko, V. Isachenko, Roy A. Jensen, I. I. Katkov, S. Samuel Kim, Jennifer Klemp, Larissa A. Korde, R. Kreienberg, Srinivasan Krishnamurthy, Juergen Liebermann, J. Ryan Martin, Elizabeth A. McGee, Marie McLaughlin, P. Mathevet, D. Meirow, Philippe Morice, Steven F. Mullen, Kutluk Oktay, Pasquale Patrizio, Antonio Pellicer, Pinki K. Prasad, Kenny A. Rodriguez-Wallberg, Erin Rohde, Allison B. Rosen, Zev Rosenwaks, María Sánchez, R. Sanchez, Glenn L. Schattman, Peter N. Schlegel, Einat Shalom-Paz, Lonnie D. Shea, Gunapala Shetty, Jill Simmons, Carrie A. Smith, J. Smitz, Miquel Solé, Jean Squifflet, Shane R. Stecklein, Jerome F. Strauss, David J. Tagler, Seang Lin Tan, Evelyn E. Telfer, Sreedhar Thirumala, Michael J. Tucker, Catherine Uzan, Anne Van Langendonckt, Anna Veiga, W. H. B. Wallace, Wenjia Wang, Brent Waters, Dagan Wells, Teresa K. Woodruff, Erik Woods, Christine Wyns
- Edited by Jacques Donnez, Université Catholique de Louvain, Belgium, S. Samuel Kim, University of Kansas
-
- Book:
- Principles and Practice of Fertility Preservation
- Published online:
- 04 February 2011
- Print publication:
- 03 February 2011, pp x-xiv
-
- Chapter
- Export citation
Contributors
-
- By Shamsuddin Akhtar, Greg Albert, Sidney Allison, Muhammad Anwar, Haruo Arita, Amanda Barker, Mary Hanna Bekhit, Jeanna Blitz, Tyson Bolinske, David Burbulys, Asokumar Buvanendran, Gregory Cain, Keith A. Candiotti, Daniel B. Carr, Derek Chalmers, John Charney, Rex Cheng, Roger Chou, Keun Sam Chung, Anna Clebone, Frederick Conlin, Susan Dabu-Bondoc, Tiffany Denepitiya-Balicki, Jeanette Derdemezi, Anahat Kaur Dhillon, Ho Dzung, Juan Jose Egas, Stephen M. Eskaros, Zhuang T. Fang, Claudia R. Fernandez Robles, Victor A. Filadora, Ellen Flanagan, Dan Froicu, Allison Gandey, Nehal Gatha, Boris Gelman, Christopher Gharibo, Muhammad K. Ghori, Brian Ginsberg, Michael E. Goldberg, Jeff Gudin, Thomas Halaszynski, Martin Hale, Dorothea Hall, Craig T. Hartrick, Justin Hata, Lars E. Helgeson, Joe C. Hong, Richard W. Hong, Balazs Horvath, Eric S. Hsu, Gabriel Jacobs, Jonathan S. Jahr, Rongjie Jaing, Inderjeet Singh Julka, Zeev N. Kain, Clinton Kakazu, Kianusch Kiai, Mary Keyes, Michael M. Kim, Peter G. Lacouture, Ryan Lanier, Vivian K. Lee, Mark J. Lema, Oscar A. de Leon-Casasola, Imanuel Lerman, Philip Levin, Steven Levin, JinLei Li, Eric C. Lin, Sharon Lin, David A. Lindley, Ana M. Lobo, Marisa Lomanto, Mirjana Lovrincevic, Brenda C. McClain, Tariq Malik, Jure Marijic, Joseph Marino, Laura Mechtler, Alan Miller, Carly Miller, Amit Mirchandani, Sukanya Mitra, Fleurise Montecillo, James M. Moore, Debra E. Morrison, Philip F. Morway, Carsten Nadjat-Haiem, Hamid Nourmand, Dana Oprea, Sunil J. Panchal, Edward J. Park, Kathleen Ji Park, Kellie Park, Parisa Partownavid, Akta Patel, Bijal Patel, Komal D. Patel, Neesa Patel, Swati Patel, Paul M. Peloso, Danielle Perret, Anthony DePlato, Marjorie Podraza Stiegler, Despina Psillides, Mamatha Punjala, Johan Raeder, Siamak Rahman, Aziz M. Razzuk, Maggy G. Riad, Kristin L. Richards, R. Todd Rinnier, Ian W. Rodger, Joseph Rosa, Abraham Rosenbaum, Alireza Sadoughi, Veena Salgar, Leslie Schechter, Michael Seneca, Yasser F. Shaheen, James H. Shull, Elizabeth Sinatra, Raymond S. Sinatra, Neil Singla, Neil Sinha, Denis V. Snegovskikh, Dmitri Souzdalnitski, Julie Sramcik, Zoreh Steffens, Alexander Timchenko, Vadim Tokhner, Marc C. Torjman, Co T. Truong, Nalini Vadivelu, Ashley Vaughn, Anjali Vira, Eugene R. Viscusi, Dajie Wang, Shu-ming Wang, J. Michael Watkins-Pitchford, Steven J. Weisman, Ira Whitten, Bryan S. Williams, Jeremy M. Wong, Thomas Wong, Christopher Wray, Yaw Wu, Anthony T. Yarussi, Laurie Yonemoto, Bita H. Zadeh, Jill Zafar, Martha Zegarra, Keren Ziv
- Edited by Raymond S. Sinatra, Jonathan S. Jahr, University of California, Los Angeles, School of Medicine, J. Michael Watkins-Pitchford
-
- Book:
- The Essence of Analgesia and Analgesics
- Published online:
- 06 December 2010
- Print publication:
- 14 October 2010, pp xi-xviii
-
- Chapter
- Export citation
Rogues' Gallery of Contributing Authors
-
- By Ramon Abola, Rishimani Adsumelli, Syed Azim, Tazeen Beg, Helene Benveniste, Louis Chun, Ramtin Cohanim, Dominick Coleman, Joseph Conrad, Tommy Corrado, Jason Daras, Michelle DiGuglielmo, Vedan Djesevic, Andrew Drollinger, Kathleen Dubrow, Brian Durkin, Ralph Epstein, Christopher J. Gallagher, Xiaojun Guo, Sofie Hussain, Ron Jasiewicz, Anna Kogan, Ursula Landman, Rany Makaryus, Daryn Moller, Tate Montgomery, Matthew Neal, Khoa Nguyen, Marco Palmieri, Shaji Poovathor, Eric Posner, Deborah Richman, Andrew Rozbruch, Misako Sakamaki, Joy Schabel, Bharathi Scott, Peggy Seidman, Shiena Sharma, Vishal Sharma, Ellen Steinberg, Neera Tewari, Jane Yi, Jonida Zeqo, Peter Chung, John Denny, Steven H. Ginsberg, Jeremy Grayson, Jonathan Kraidin, Stephen Lemke, Tejal Patel, Salvatore Zisa, Charles Cowles, Marc Rozner, Shawn Banks, Deborah Brauer, Lebron Cooper, V. Samepathi David, Steve Gayer, Steven Gil, Eric A. Harris, Murlikrishna Kannan, Michael C. Lewis, David A. Lindley, Carlos M. Mijares, Sana Nini, Shafeena Nurani, Sujatha Pentakota, Edgar Pierre, Amy Klash Pulido, Michael Rossi, Miguel Santos, Nancy Setzer-Saade, Adam Sewell, Omair H. Toor, Ashish Udeshi, Patricia Wawroski, Lauren C. Berkow, Dan Berkowitz, Ramola Bhambhani, Kerry K. Blaha, Veronica Busso, Adam J. Carinci, Paul J. Christo, R. Blaine Easley, Ralph J. Fuchs, Samuel M. Galvagno, Nishant Gandhi, Andrew Goins, Robert S. Greenberg, Sayeh Hamzehzadeh, Theresa L. Hartsell, Eugenie Heitmiller, Jeremy M. Huff, Brijen L. Joshi, Sapna Kudchadkar, Jennifer K. Lee, Ira Lehrer, Peter Lin, Justin Lockman, Christine L. Mai, Christina Miller, Nanhi Mitter, Gillian Newman, Daniel Nyhan, Lale Odekon, Rabi Panigrahi, Melissa Pant, Alexander Papangelou, Mark Rossberg, Adam Schiavi, Steven J. Schwartz, Deborah A. Schwengel, Brandon M. Togioka, Tina Tran, Emmett Whitaker, Bradford D. Winters, Christopher Wu, Elena J. Holak, Paul S. Pagel
- Edited by Christopher J. Gallagher, State University of New York, Stony Brook, Michael C. Lewis, University of Miami School of Medicine, Deborah A. Schwengel
-
- Book:
- Core Clinical Competencies in Anesthesiology
- Published online:
- 06 July 2010
- Print publication:
- 12 April 2010, pp xi-xii
-
- Chapter
- Export citation
Qualitative magnetic resonance imaging findings in geriatric depression. Possible link between later-onset depression and Alzheimer's disease?
- B. S. GREENWALD, E. KRAMER-GINSBERG, B. BOGERTS, M. ASHTARI, P. AUPPERLE, H. WU, L. ALLEN, D. ZEMAN, M. PATEL
-
- Journal:
- Psychological Medicine / Volume 27 / Issue 2 / March 1997
- Published online by Cambridge University Press:
- 01 March 1997, pp. 421-431
-
- Article
- Export citation
-
Background. Several clinical and neuroimaging investigations support the notion that underlying brain changes may relate to depression in older patients, especially those with a later-age initial episode. However uncertainty still exists about diagnostic and pathogenic significance of structural brain abnormalities in aged depressives, in part because many studies lack all-elderly and age-similar normal comparison populations.
Methods. Brain morphology of elderly depressives (N = 30) and normal controls (N = 36) was compared by assessing magnetic resonance imaging (MRI) brain scans with qualitative criteria-based scales. Ratings included lateral and third ventricle enlargement, and cortical, medial temporal, and caudate atrophy.
Results. Significant differences between depressed and control groups were not demonstrated. Later-onset depressives had significantly more left medial temporal and left caudate atrophy than early-onset counterparts of similar age. Medial temporal atrophy significantly correlated with cognitive impairment and was not related to physical illness. Depressives with medial temporal atrophy (N = 7) were older and had later age at onset of depression than those without such changes. Cerebrovascular disease risk factors did not predict MRI abnormalities.
Conclusions. Results indicate non-specificity and lack of homogeneity of qualitatively measured structural brain changes in geriatric depression, but suggest that pathology of specific, lateralized brain regions may be implicated in some later-onset patients. The relationship between medial temporal atrophy and late-onset depression raises the possibility that such patients may suffer from as-yet undeclared Alzheimer's disease. Lack of association between cerebrovascular disease risk factors and brain changes suggests other pathophysiological contributions.
13 - The book of Daniel
-
- By H. L. Ginsberg, The Jewish Theological Seminary of America, New York
- Edited by W. D. Davies, Louis Finkelstein
-
- Book:
- The Cambridge History of Judaism
- Published online:
- 28 March 2008
- Print publication:
- 22 March 1990, pp 504-523
-
- Chapter
- Export citation
-
Summary
It is clear that the book of Daniel falls into two quite different parts: Daniel A, chapters 1–6, the book of court stories, and Daniel B, chapters 7 to 12, the book of apocalypses. Because the historical background of B is, as was first pointed out by the neo-Platonist philosopher Porphyry (circa 260 c.e.) – whom Jerome quotes in order to polemize against him – unmistakably the period when the Seleucid King Antiochus IV Epiphanes (175–163 b.c.e.) first persecuted and then outlawed Judaism, the prevailing critical opinion in the late nineteenth and early twentieth centuries, of which S. R. Driver's commentary entitled The Book of Daniel (first printed in 1900 and repeatedly reprinted) is a good representative, was that the entire book was produced during that period, though it was admitted that what we have dubbed Daniel A made use of older traditions. During the first half of the twentieth century, however, an impressive number of reputable scholars insisted that there was not the slightest reflection of, let alone allusion to, the Epiphanian situation in Daniel A without benefit of midrash, and therefore assigned a pre-Epiphanian date to it. During the third quarter of our century, however, there has been a retreat to the older critical view. That the reaction is a retrogression will, it is hoped, become clear from the following exposition. [There is considerable agreement between it and the commentary of L. F. Hartman and A. A. Di Lela, The Book of Daniel, AB 23 (Garden City, 1978) (who have adopted many of the present author's previously published views), but it was already in the editorial hopper when their volume came out.]
Notes on “The Birth of the Gracious and Beautiful Gods”
- H. L. Ginsberg
-
- Journal:
- Journal of the Royal Asiatic Society of Great Britain and Ireland (New Series) / Volume 67 / Issue 1 / January 1935
- Published online by Cambridge University Press:
- 15 March 2011, pp. 45-72
- Print publication:
- January 1935
-
- Article
- Export citation
-
The new Has Shamra text published by Virolleaud is, despite better preservation, considerably more difficult to interpret than its two immediate predecessors, and in this regard resembles rather the fragments of 1929.
![](/core/cambridge-core/public/images/lazy-loader.gif)